Patents Assigned to Synermore Biologics Co., Ltd.
  • Anti-EGFR antibody and uses of same
    Patent number: 10759860
    Abstract: This disclosure relates generally to an EGFR antibody and its therapeutic effects on tumor inhibition in vitro and in vivo, alone or in combination with various chemotherapeutic agents. In particular, the present disclosure relates to methods for the treatment of cancer, comprising administering an EGFR antibody, alone or in combination with a chemotherapeutic agent.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: September 1, 2020
    Assignee: Synermore Biologics Co., Ltd.
    Inventor: Eric Tsao